A combination of fluoropyrimidine with or without oxaliplatin is often administered as a neoadjuvant chemotherapy to treat colon cancer, but its effectiveness isn’t well established. Adjuvant ...

Adding adjuvant chemotherapy to radiotherapy did not lead to a significant survival benefit over radiotherapy alone in women ...

A new study links changes in frailty, a measure of decreased physiological capacity that leads to fatigue, slow walking, muscle weakness, physical inactivity, and weight loss, to five-year survival ...

The European Commission on Friday approved AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo's (OTC:DSKNY) Enhertu (trastuzumab ...

The addition of nivolumab to neoadjuvant chemotherapy significantly increased pathologic complete response among certain ...

Toxicity related to the systematic delivery of IL-12, a well-known and widely researched anti-tumor cytokine, has limited its ...

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the European Commission (EC) to ...

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

Imfinzi in combination with chemotherapy has been approved in the European Union, EU, for the treatment of adults with ...

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone ...

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation ...